NOTE TO READERS: When this project lost substantial funding at the end of 2018, I lost the ability to continue publishing criteria-driven news story reviews and PR news release reviews - once the bread-and-butter of the site going back to 2006. The 3,200 archived reviews, while still educational, are getting old and difficult for me to technically maintain on the back end of the website. So I am announcing that I plan to remove these reviews from the site by April 1, 2021. The blog and the toolkit - two of the most popular features on the site - will remain. If you wish to peruse the reviews before they disappear, please do so by the end of March 2021. After that date you may still be able to access them via the Internet Archive Wayback Machine - https://archive.org/web/.

Tags: FDA

8/24/2018

Without an independent source, BuzzFeed’s story on a medical device for OCD doesn’t offer much beyond the news release

5 10/25/2017

Brief but informative report from AP on newly approved shingles vaccine

7/18/2017

Washington Post wisely notes that CAR T-cell therapy may cost at least $300,000

4/14/2017

Lack of independent sources hinders AP story on new drug that treats side effect caused by antipsychotics

1/8/2016

Tacos and neural tube defects: NPR deftly explains the connection

1 11/13/2015

WSJ whiffs on meaningful aspects of new melanoma drug approval — including $17,600/month price tag

2/17/2012

Weight-Loss Drugs Face High Hurdles At FDA

2/1/2012

FDA Approves Cystic Fibrosis Drug

4/18/2011

FDA Approves New Device for Brain Tumor Treatment

2/5/2011

FDA Approves First Drug To Prevent Preterm Births

Story Reviews

Systematic, Criteria-Driven

@HealthNewsRevu

Retweet on TwitterHealthNewsReview.org Retweeted
AKECasselsAlan Cassels@AKECassels·

Puleeeeease... this 'game changer' weight loss drug causes more nausea and vomiting than a placebo. Some game, some change. My friend Gary would spank you for using the eighth word medical reporters should never, ever use. @garyschwitzer @thackerpd
https://www.healthnewsreview.org/toolkit/just-journalists-writing-tips-case-studies/7-words-and-more-you-shouldnt-use-in-medical-news/ https://twitter.com/OttawaCitizen/status/1361426796126830597

Reply on Twitter 1361431489326407680Retweet on Twitter 13614314893264076804Like on Twitter 13614314893264076807Twitter 1361431489326407680
Retweet on TwitterHealthNewsReview.org Retweeted
RxISKRxISK@RxISK·

A scary @statnews Op-Ed warns that govt attempts to rein in Pharma may cut off access to "life-changing" drugs.

It takes @garyschwitzer to let us know: the author spent 10 years as Pfizer's public-policy chief. https://twitter.com/garyschwitzer/status/1360325022578053123

Reply on Twitter 1361420459284131843Retweet on Twitter 13614204592841318437Like on Twitter 136142045928413184313Twitter 1361420459284131843
HealthNewsRevuHealthNewsReview.org@HealthNewsRevu·

.@TranspariMED criticizes STAT op-ed for not disclosing pharma funding of author’s institute - similar to criticism we’ve made of STAT op-eds in the past. @transparify @ThinkTankWatch @icer_review https://www.healthnewsreview.org/2021/02/transparency-watchdog-criticizes-stats-non-disclosure-on-pro-pharma-op-ed/

Reply on Twitter 1360214949704982532Retweet on Twitter 13602149497049825323Like on Twitter 13602149497049825328Twitter 1360214949704982532
View More

Categories

View More

Tags